ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin

In recent years the introduction of target therapies with BRAF and MEK inhibitors (MAPKi) and of immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies have dramatically improved survival of metastatic melanoma patients. Despite these changes drug resistance remains a major hurdle. Sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggiero, Ciro Francesco, Malpicci, Debora, Fattore, Luigi, Madonna, Gabriele, Vanella, Vito, Mallardo, Domenico, Liguoro, Domenico, Salvati, Valentina, Capone, Mariaelena, Bedogni, Barbara, Ascierto, Paolo Antonio, Mancini, Rita, Ciliberto, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826737/
https://www.ncbi.nlm.nih.gov/pubmed/31557826
http://dx.doi.org/10.3390/cancers11101425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826737/
https://www.ncbi.nlm.nih.gov/pubmed/31557826
http://dx.doi.org/10.3390/cancers11101425

Ejemplares similares